COR

Cencora Inc.
NYSEHEALTHCAREMEDICAL DISTRIBUTION

Key Statistics

Market Cap
$63.65B
P/E Ratio
18.92
EPS
$17.63
Beta
0.57
52W High
$375.33
52W Low
$243.78
50-Day MA
$325.11
200-Day MA
$316.79
Dividend Yield
0.71%
Profit Margin
1.03%
Forward P/E
17.06
PEG Ratio
0.71

About Cencora Inc.

CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.

Official WebsiteUSAFY End: September

Fundamentals

Revenue (TTM)$337.40B
Gross Profit (TTM)$13.80B
EBITDA$5.72B
Operating Margin1.27%
Return on Equity129.00%
Return on Assets3.57%
Revenue/Share (TTM)$1746.56
Book Value$19.29
Price-to-Book17.61
Price-to-Sales (TTM)0.19
EV/Revenue0.211
EV/EBITDA11.64
Quarterly Earnings Growth (YoY)11.90%
Quarterly Revenue Growth (YoY)5.50%
Shares Outstanding$190.83M
Float$180.25M
% Insiders4.31%
% Institutions99.44%

Historical Volatility

HV 10-Day
35.96%
HV 20-Day
28.45%
HV 30-Day
26.94%
HV 60-Day
24.20%
HV Rank
63.1%

Volatility is currently expanding

Analyst Ratings

Consensus ($371.67 target)
3
Strong Buy
7
Buy
4
Hold

Latest News

What Cencora (COR) Said on Its Q4 Earnings Call

Cencora NYSE: COR reported higher fiscal fourth-quarter revenue and adjusted earnings as specialty drug sales and its acquisition of OneOncology contributed to growth. The company also introduced a new reporting structure that separates its specialty operations from its broader pharmaceutical distribution business.

MarketBeat11/5/2026Neutral
Cencora (COR) Reports Q4 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Cencora (COR) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Investment Research11/4/2026Positive
Cencora Announces New Organizational and Reporting Structure to Enhance Visibility and Focus

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it is realigning its corporate and reporting structure to strengthen execution and visibility. “Over the last two years, Cencora has taken significant steps to advance our strategy through investments to further our leadership in specialty and enhance our service to our customers and partners. Our realigned organizational structure reflects our focus on ensuring Cencora is uniquely positioned as a leader in suppo.

Business Wire11/4/2026Neutral
Cencora Reports Fiscal 2026 Fourth Quarter and Fiscal Year End Results

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2026 fourth quarter ended September 30, 2026, revenue increased 5.5 percent to $88.4 billion. Revenue increased 5.0 percent to $337.4 billion for fiscal year 2026. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.71 for the fourth quarter of fiscal 2026, compared to $(1.75) in the prior year quarter. Adjusted diluted EPS, which is a no.

Business Wire11/4/2026Neutral
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Lumentum Holdings Inc. (Nasdaq – LITE), Surgery Partners, Inc. (Nasdaq – SGRY), Range Resources Corporation (NYSE – RRC), American Oncology Network, Inc. (OTCQX – AONC)

BALA CYNWYD, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.

GlobeNewsWire11/2/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on COR and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 11/7/2026